Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends.

Literature DB >> 27080148

Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends.

Abstract

Antibody-drug conjugates (ADCs) are emerging modalities in the pharmaceutical industry. The unique target-specific binding of antibody allows targeted delivery of cytotoxic small molecules to cancer cells, and thus expands the therapeutic window. However, in-depth characterization of ADCs is complex because it involves the characterization of antibody, conjugated molecules and antibody conjugates as a whole. In this review, we describe the practical use of mass spectrometry for ADC characterization including qualitative and quantitative analysis. Technical advances, limitations and future trends will also be discussed.

Entities: Disease

Mesh：

Substances：

Year: 2016 PMID： 27080148 DOI： 10.1016/j.drudis.2016.04.004

Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851

Keyword Cloud
Cited

13 in total

1. Conformational Assessment of Adnectin and Adnectin-Drug Conjugate by Hydrogen/Deuterium Exchange Mass Spectrometry.

Authors: Richard Y-C Huang; Steven R O'Neil; Daša Lipovšek; Guodong Chen
Journal: J Am Soc Mass Spectrom Date: 2018-05-07 Impact factor: 3.109

2. A Tiered Approach for Characterization to Ensure Quality, Reproducibility, and Long-Term Stability of Critical Reagents in Regulated Bioanalysis to Support PK/ADA/NAb Assays for Biologics and Vaccines Programs.

Authors: Kun Yang; Ying Zhang; Robert Chou; Lai Yeung; Simon Letarte; Rong-Sheng Yang; Xuanwen Li; Maribel Beaumont; Rico Gunawan; Douglas Richardson; Shara Dellatore; Eric Woolf; Yang Xu
Journal: ACS Pharmacol Transl Sci Date: 2020-10-28

Review 3. Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.

Authors: Olga V Friese; Jacquelynn N Smith; Paul W Brown; Jason C Rouse
Journal: MAbs Date: 2018-02-20 Impact factor: 5.857

4. The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry.

Authors: Renpeng Liu; Xuan Chen; Junia Dushime; Megan Bogalhas; Alexandru C Lazar; Thomas Ryll; Lintao Wang
Journal: MAbs Date: 2017-01-31 Impact factor: 5.857

Review 5. Glycoengineering of Antibodies for Modulating Functions.

Authors: Lai-Xi Wang; Xin Tong; Chao Li; John P Giddens; Tiezheng Li
Journal: Annu Rev Biochem Date: 2019-03-27 Impact factor: 23.643

6. Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control.

Authors: Yubo Tang; Feng Tang; Yang Yang; Lei Zhao; Hu Zhou; Jinhua Dong; Wei Huang
Journal: Sci Rep Date: 2017-08-10 Impact factor: 4.379

Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends.

1. Conformational Assessment of Adnectin and Adnectin-Drug Conjugate by Hydrogen/Deuterium Exchange Mass Spectrometry.

2. A Tiered Approach for Characterization to Ensure Quality, Reproducibility, and Long-Term Stability of Critical Reagents in Regulated Bioanalysis to Support PK/ADA/NAb Assays for Biologics and Vaccines Programs.

Review 3. Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.

4. The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry.

Review 5. Glycoengineering of Antibodies for Modulating Functions.

6. Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control.

7. Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering.

8. Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates.

9. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.

Review 10. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.